



Rexahn Pharmaceuticals, Inc.  
Investor Relations Department  
15245 Shady Grove Road, Suite  
455  
Rockville, MD 20850  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	2.28
Trade Time:	4:10 PM ET 07/27/17
Change:	-0.08 ↓ (3.386%)
Day Range	2.25 - 2.37
52-Week Range	1.27 - 7.10
Volume	119,538

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- [07/10/17  
Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117](#)
- [06/07/17  
Rexahn Announces \\$10 Million Registered Direct Offering](#)
- [06/04/17  
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology \(ASCO\) 2017 Annual Meeting](#)
- [05/08/17  
Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology \(ASCO\) 2017 Annual Meeting](#)
- [05/05/17  
Rexahn Effects 1-for-10 Reverse Stock Split](#)

## Financials [\[ View all \]](#)

- [Fourth Quarter Financial Results](#)
- [02/24/17  
Annual Report \(10-K\)](#)
- [02/24/17  
Proxy Statement \(DEF 14A\)](#)
- [05/03/17  
Quarterly Report \(10-Q\)](#)
- [11/04/16  
Quarterly Report \(10-Q\)](#)
- [08/05/16  
Quarterly Report \(10-Q\)](#)